DiaMedica Therapeutics Inc. (DMAC) |
| 6.54 0.24 (3.81%) 04-14 16:00 |
| Open: | 6.33 |
| High: | 6.545 |
| Low: | 6.25 |
| Volume: | 142,377 |
| Market Cap: | 352(M) |
| PE Ratio: | -9.34 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 8.13 |
| Resistance 1: | 7.21 |
| Pivot price: | 6.54 |
| Support 1: | 5.71 |
| Support 2: | 4.75 |
| 52w High: | 10.4195 |
| 52w Low: | 3.2805 |
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Financials
| EPS | -0.710 |
| Book Value | 0.990 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -38.3 |
| Return on Equity (ttm) | -64.1 |
Company news
Mon, 13 Apr 2026
EBITDA per share of DiaMedica Therapeutics Inc. – NASDAQ:DMAC - TradingView — Track All Markets
Thu, 02 Apr 2026
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Diamedica Therapeutics (DMAC), Elevance Health (ELV) and Oric Pharmaceuticals (ORIC) - The Globe and Mail
Tue, 31 Mar 2026
DiaMedica Therapeutics Inc (DMAC) Q4 2025 Earnings Call Highlights: Strong Cash Position and ... By GuruFocus - Investing.com Canada
Mon, 30 Mar 2026
DiaMedica Therapeutics Inc. - Common Stock (DMAC) Stock Price, News, Quote & History - FinancialContent
Mon, 30 Mar 2026
Top Wall Street Forecasters Revamp DiaMedica Therapeutics Expectations Ahead Of Q4 Earnings - Sahm
Mon, 30 Mar 2026
Rising R&D widens loss as DiaMedica (NASDAQ: DMAC) funds DM199 - Stock Titan
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
